• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
OVID

OVID

Ovid Therapeutics Inc.

NASDAQHealthcareBiotechnologyUS

USD2.39

-0.01 (-0.42%)

Rating:C+

Company Profile

CEO

Margaret Alexander

IPO Date

2017-05-05

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$2.38

Prev. Close

$2.40

Day Low

$2.32

Day High

$2.47

52W Low

$0.27

52W High

$3.10

Market Cap

$0.32B

Volume

2.20M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

48.3%

Avg Negative

11.3%

Avg Neutral

40.6%

News Feed

Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities

GlobeNewsWire·7/8/2021·↓ negative

Ovid Therapeutics: Good Entry Point For Investors

Seeking Alpha·6/18/2021·↑ positive

Ovid Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

GlobeNewsWire
·5/12/2021
·↑ positive

OVID Stock Price Increased Over 5% Pre-Market: Why It Happened

Pulse2·3/30/2021·↑ positive

OVID Stock News: The Big Deal That Has Ovid Therapeutics Rocketing Higher Today

InvestorPlace·3/3/2021·↑ positive

Ovid Shares Rally On Soticlestat Development Pact With Takeda In Rare Epilepsy Syndromes

Benzinga·3/3/2021·↑ positive

OVID Stock Price Increases Over 60% Pre-Market: Why It Happened

Pulse2·3/3/2021·↑ positive

Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index

GlobeNewsWire·12/16/2020·↑ positive

Why Ovid Therapeutics Stock Is Imploding Today

The Motley Fool·12/2/2020·↓ negative

Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint

GlobeNewsWire·12/1/2020·↑ positive